Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.
Euro Surveill. 2024 Jan;29(1). doi: 10.2807/1560-7917.ES.2024.29.1.2300703.
We present early vaccine effectiveness (VE) estimates of the 2023 seasonal COVID-19 XBB.1.5 vaccine against COVID-19 hospitalisation and admission to an intensive care unit (ICU) in previously vaccinated adults ≥ 60 years in the Netherlands. We compared vaccination status of 2,050 hospitalisations including 92 ICU admissions with age group-, sex-, region- and date-specific population vaccination coverage between 9 October and 5 December 2023. VE against hospitalisation was 70.7% (95% CI: 66.6-74.3), VE against ICU admission was 73.3% (95% CI: 42.2-87.6).
我们报告了 2023 年季节性 COVID-19 XBB.1.5 疫苗在荷兰≥60 岁既往接种过疫苗的成年人中的 COVID-19 住院和入住重症监护病房（ICU）的早期疫苗有效性（VE）估计值。我们比较了 2023 年 10 月 9 日至 12 月 5 日期间 2050 例住院病例（包括 92 例 ICU 入院）与年龄组、性别、地区和特定日期的人群疫苗接种覆盖率。疫苗对住院的有效性为 70.7%（95%可信区间：66.6-74.3），对 ICU 入院的有效性为 73.3%（95%可信区间：42.2-87.6）。
Zotero 插件